Doha: Argus Cognitive and Qatar Biomedical Research Institute signed an agreement to support the early diagnosis of Autism Spectrum Disorder.
This collaboration will have a positive impact on the health of the people of Qatar and also aligns with the vision of QBRI’s Neurological Disorders Research Center.
ADOS-2 (Autism Diagnostic Observation schedule-2) will use machine learning and artificial intelligence.
Dr Fouad Alshaban, a Senior Scientist at the Neurological Disorders Research Center (NDRC) at QBRI, says through the new tool, the diagnosis will not be based on the experience of the person conducting the test.
In most medical centres the doctor observes the patient and bases his or her understanding of the condition on this, determining whether the patient has autism or not.
In order to examine the expression of the patient, an eye-tracking glass will be used by the person administering the test. The room where the test is conducted will have three cameras. The first will gives the view of the full room, the second will be on the person conducting the test and the third will focus on the patient.
The data gathered from the test will be then channelled to machine learning and AI which will determine whether the patient has autism or not.